Nutritional composition for promoting osteogenesis, protecting articular cartilage and improving joint inflammation

Abstract

The invention discloses a nutritional composition for promoting osteogenesis, protecting articular cartilage and improving joint inflammation, and belongs to the technical field of bone health products. According to the invention, the components in the formula and the proportion thereof are systematically researched and analyzed to construct a nutritional composition formula system which takes yak bone collagen peptide as a main material and shark cartilage powder as an auxiliary material, and is added with an effective amount of non-denatured type II collagen and vitamin K2 to promote osteogenesis, protect articular cartilage and improve joint inflammation. On the basis of research on bioactive substances in combination with the modern nutriology theory, the best combination between bone collagen peptide and cartilage powder, between vitamin K2 and bone collagen peptide and between non-denatured type II collagen and bone collagen is found through tests, the synergistic effect is achieved, and the bone nutrition effect is extremely good. Functional tests and testee people prove that the nutritional composition has the effects of promoting osteogenesis, protecting articular cartilage and improving joint inflammation.

Description

Technical Field

[0001] This invention relates to the field of bone health products technology, specifically to a nutritional composition that promotes bone growth, protects articular cartilage, and improves joint inflammation, and its preparation method. Background Technology

[0002] Bone health is a dynamic process that spans the entire lifespan. Bone loss can easily affect bone health; for example, osteoporosis and osteoarthritis are manifestations of bone loss. Arthritis refers to inflammatory diseases affecting the joints and surrounding tissues. Clinically, it manifests as redness, swelling, heat, pain, impaired function, and joint deformities, which can lead to joint disability in severe cases. Pain is one of the most prominent symptoms of arthritis. Joint pain and swelling of the surrounding tissues caused by inflammation can restrict joint movement. The occurrence of this disease is closely related to age and living environment, and its prevalence gradually increases with age.

[0003] Osteoarthritis is a syndrome of joint pain and dysfunction caused by degenerative changes in the joints. It is characterized by joint pain and functional impairment, with late-stage symptoms including joint contractures, muscle atrophy, and limb deformities. Knee osteoarthritis is a common clinical orthopedic disease, primarily affecting middle-aged and elderly individuals. Its occurrence is mostly due to factors such as joint degeneration, local injury, chronic strain, and inflammatory responses. Knee pain and joint dysfunction are common clinical symptoms, and the condition is prone to recurrence, severely reducing patients' ability to engage in daily activities and impacting both their physical and mental health. Effective prevention and management are currently a hot topic and a significant challenge.

[0004] With the increasing aging of the population, the incidence of bone and joint diseases is rising, such as arthritis, osteoporosis, and osteoarthritis caused by bone and joint wear and tear. This condition is mainly concentrated in middle-aged and elderly people. According to information disclosed by the WHO, approximately 528 million people worldwide suffered from osteoarthritis in 2019. In my country, the overall prevalence of primary osteoarthritis in people over 40 years of age is 46.3%, with a prevalence of 30.10% in the 40-49 age group, 48.70% in the 50-59 age group, 62.2% in the 60-69 age group, and 62.10% in the 70 and above age group. It is evident that the prevalence gradually increases with age, and the prevalence varies in different body parts, with the following order of prevalence: lumbar spine (29.4%), cervical spine (23.6%), both knees (15.6%), and both hands (7.8%). Furthermore, the prevalence of osteoporosis gradually increases with age. In my country, the prevalence rate among people over 60 years old is higher in southern regions than in northern regions, at 39.7% and 35.7% respectively. The prevalence is also higher in women than in men. This large prevalence poses a significant threat to bone health, making addressing bone health issues an urgent need. According to a study published in the Peking Union Medical College Journal by the Institute for Health Metrics and Evaluation (IHME), the world's largest public health research project, approximately 640 million, 280 million, 60 million, and 120 million patients worldwide will suffer from osteoarthritis of the knee, hand, hip, and other joints by 2020, representing increases of 74.9%, 48.6%, 78.6%, and 95.1% respectively compared to 2020. In 2019, Chinese scholars predicted that the number of people suffering from osteoarthritis in my country will continue to rise before 2044, with the number of patients expected to increase to 1.5 times that of 2019. Given the close relationship between bone and joint health and multidisciplinary diseases, focusing on bone and joint health will become an inevitable trend.

[0005] Current technologies suggest that bone health can be improved by consuming collagen peptides and cartilage extracts.

[0006] For example, patent application number CN202411432265.9 discloses a nutritional composition for improving bone and joint health. By mass, the composition comprises the following components: 0.5-5 parts collagen peptides, 5-30 parts mangosteen extract, 0.5-3 parts non-denatured type II collagen peptides, 0.1-2 parts milk mineral salts, 0.3-3 parts bone collagen peptides, 0.1-2 parts cartilage extract, 0.1-2 parts N-acetylglucosamine, 0.1-2 parts sodium hyaluronate, and 0.3-3 parts turmeric extract.

[0007] For example, patent application number CN202510060022.5 discloses a composition of collagen peptides that enhances immune stimulation and promotes osteoblast synthesis, comprising the following components by mass percentage: taurine 0.05-0.2%, vitamin C 0.1%-1%, type II collagen peptides 5%-20%, type III collagen peptides 5%-20%, and the balance being bovine bone collagen peptides.

[0008] For example, patent application number CN201811175742.2 discloses a composition for the prevention and treatment of osteoarthritis, which contains: non-denatured type II collagen and chondroitin peptides, and the weight ratio of the non-denatured type II collagen to the chondroitin peptides is 1:1-20.

[0009] Through experiments, the applicant discovered that by continuously optimizing the varieties of collagen peptides, cartilage extracts, and the ratio of non-denatured type II collagen, vitamin K2, fruit powder, and fruit powder flavoring, a nutritional composition was obtained that can further enhance bone growth, protect articular cartilage, and improve joint inflammation. Summary of the Invention

[0010] This invention provides a nutritional composition and its preparation method for promoting bone growth, protecting articular cartilage, and improving joint inflammation. Through systematic research and analysis of the components and their proportions in the formula, this invention constructs a nutritional composition system with yak bone collagen peptides as the main component, (shark) cartilage powder as an auxiliary component, and the addition of effective amounts of non-denatured type II collagen and vitamin K2 to enhance bone growth, protect articular cartilage, and improve joint inflammation. Furthermore, combining modern nutritional theories on the utilization of bioactive substances in the human body, experiments have revealed the optimal combination of bone collagen peptides and cartilage powder, vitamin K2 and bone collagen peptides, and non-denatured type II collagen and bone collagen, achieving a synergistic effect with excellent bone nutrition benefits. The specific technical solution provided by this invention is as follows: On one hand, embodiments of the present invention provide a nutritional composition for promoting bone growth, protecting articular cartilage, and improving joint inflammation, comprising the following components in parts by weight: 60-80 parts of yak bone collagen peptide, 15-25 parts of (shark) cartilage powder, 8-16 parts of fruit powder, 0.1-0.3 parts of non-denatured type II collagen, and 0.002-0.004 parts of vitamin K2.

[0011] Furthermore, the nutritional composition in the embodiments of the present invention also includes fruit powder and flavoring to improve taste and aroma.

[0012] The fruit powder is selected from strawberry powder, sweet orange powder, or blueberry powder, etc., and the flavoring is selected from strawberry flavoring, sweet orange flavoring, or blueberry flavoring, etc. Preferably, the fruit powder is selected from sweet orange powder, and the flavoring is selected from sweet orange flavoring.

[0013] Preferably, the nutritional composition provided by the present invention comprises the following components in parts by weight: 70 parts yak bone collagen peptide, 20 parts (shark) cartilage powder, 12 parts fruit powder, 0.2 parts non-denatured type II collagen, and 0.002 parts vitamin K2.

[0014] More preferably, the composition provided by the present invention comprises the following components in parts by weight: 70 parts yak bone collagen peptide, 20 parts (shark) cartilage powder, 12 parts sweet orange powder, 0.2 parts non-denatured type II collagen, 0.002 parts vitamin K2, and 1 part sweet orange flavoring.

[0015] The nutritional composition of this invention is rich in various essential amino acids, chondroitin sulfate, calcium, collagen, and vitamins, which can meet the nutritional needs of special populations. Yak bone collagen peptides contain high levels of active ingredients, and their molecular structure is similar to that of the human body, making them more easily absorbed and utilized. By introducing (shark) cartilage powder, non-denatured type II collagen, and vitamin K2 in a rational combination, the synergistic effect between the components is fully utilized. This allows yak bone collagen to be used in combination with (shark) cartilage powder, or with non-denatured type II collagen, to promote bone cell proliferation, improve osteoarthritis, and relieve pain, achieving a synergistic effect greater than the sum of its parts (1+1>2). (Shark) cartilage powder is an important nutrient for cartilage health, acting as a "protector" of joints. When used alone, it promotes chondrocyte proliferation, relieves joint pain, inhibits inflammation, and protects cartilage. When used in combination with collagen peptides, it can effectively improve osteoarthritis. The fruit powder is rich in organic acids, dietary fiber, vitamin C, protein, and polysaccharides. Vitamin C works synergistically with yak bone collagen peptides to promote collagen synthesis. Non-denatured type II collagen has anti-inflammatory and analgesic effects when used alone. When used in combination with collagen and shark cartilage powder, the effect is far greater than the sum of its parts (1+1+1>3). Vitamin K2 guides calcium into bones, acting as a bone calcium "stabilizer" and a "sniper" against bone hyperplasia. It can actively guide calcium into bones by activating osteocalcin and bone matrix proteins, increasing bone density and preventing osteoporosis. Therefore, the nutritional composition of this invention has the effects of promoting bone growth, protecting articular cartilage, and improving joint inflammation.

[0016] The effects / functions of the raw and auxiliary materials used in this invention are as follows: Yak bone collagen peptides: These promote collagen production and nourish bone cells, acting as the "concrete" of bones. 22% of bone is composed of protein, primarily type I and type II collagen. The amino acids and polypeptides in protein facilitate calcium absorption. Peptides promote the proliferation of bone and cartilage cells, preventing osteoporosis, increasing bone strength and hardness, and preventing or improving joint flexibility. Peptides play a crucial role in bone growth, development, and synthesis, promoting and accelerating the growth of bone cells and tissues, strengthening bones and teeth, and enhancing immunity and metabolism.

[0017] (Shark) Cartilage Powder: A healthy nutrient for cartilage, acting as a "protector" of joints. It contains protein (collagen), chondroitin sulfate, mucopolysaccharides (such as hyaluronic acid), calcium, phosphorus, etc., and has the effects of relieving arthritis, strengthening bones, and anti-inflammatory and immune-regulating properties. Chondroitin is a common natural polysaccharide, mainly found in animal cartilage and bones. It can transport nutrients, remove waste, help cartilage retain water, and has lubricating, friction-reducing, and supportive functions. It also has health benefits such as relieving joint pain and inflammation and preventing osteoporosis.

[0018] Undenatured type II collagen (UC-II): Repairs cartilage health and acts as an "anti-inflammatory and analgesic" for joints. It is mainly found in cartilage tissue and contains collagen. Its characteristic is that it has not undergone high temperature or chemical denaturation treatment, thus retaining its natural triple helix structure. This intact structure has unique biological activity for joint health, and can relieve joint pain, improve arthritis, repair cartilage, alleviate articular cartilage degeneration, and prevent joint damage.

[0019] Vitamin K2: It can attract calcium into bones, acting as a "stabilizer" of bone calcium and a "sniper" of bone hyperplasia. Vitamin K2 can activate calcium-binding proteins and regulate bone morphogenetic proteins, guiding calcium into the bones, increasing bone density, and preventing osteoporosis. At the same time, it can also prevent calcium from depositing in soft tissues. It is a key step in the conversion of "blood calcium" into "bone calcium," which can reduce the risk of vascular calcification, protect the cardiovascular system, and address osteoporosis at its source.

[0020] Fruit powder: It can replenish the body with various active ingredients, supporting bone health. Fruit powders such as sweet oranges are rich in organic acids, dietary fiber, vitamin C, protein, and polysaccharides. In addition, they contain many functional substances, such as flavonoids and phenolic acids, which have important physiological functions such as anti-inflammatory, anti-cancer, antioxidant, and anti-allergic effects. Vitamin C can promote the synthesis of collagen in connective tissue and acidic mucopolysaccharides in the matrix. Vitamin C deficiency leads to impaired collagen synthesis, which can result in poor bone organic matter formation and osteoporosis. At the same time, vitamin C can improve calcium absorption in the small intestine, thereby promoting the body's absorption and utilization of calcium, which is beneficial for bone strengthening. In addition, the terpenoids "carotenoids" contained in fruit powders such as sweet oranges can serve as a "vitamin A source" to supplement the body's need for vitamin A, and also have anti-tumor, antioxidant, immune-regulating, and cholesterol-lowering effects. The dietary fiber content of fruit powders such as sweet oranges reaches 1-2g / 100g, which helps improve the intestinal environment, promotes defecation, and thus regulates the internal environment's sugar and lipid metabolism, improving intestinal health. The organic acids such as citric acid, malic acid, and succinic acid contained in fruit powders such as sweet oranges can increase appetite, aid food digestion, and also have antioxidant and heavy metal removal effects.

[0021] Spices are mainly used for flavoring and enhancing aroma; their core function is to provide fragrance.

[0022] On the other hand, the present invention also provides a method for preparing the aforementioned nutritional composition, the method comprising: S1: Mix (shark) cartilage powder, non-denatured type II collagen, vitamin K2 and flavoring evenly according to the formula to obtain a premix.

[0023] S2: After mixing the premix, yak bone collagen peptide and fruit powder from step S1 evenly, an intermediate product is obtained.

[0024] S3: Package the intermediate product from step S2 to obtain the final product. Attached Figure Description

[0025] Figure 1 This is a comparison of the fluorescence intensity of osteogenic bone formation in zebrafish after treatment, which facilitated the evaluation of bone function. Figure 2 This is a typical image of osteogenic fluorescence intensity in zebrafish after treatment that facilitated the evaluation of bone function; Figure 3 This is a comparison of the fluorescence intensity of osteoblasts in zebrafish after treatment to evaluate the efficacy of protecting articular cartilage; Figure 4 This is a typical fluorescence intensity diagram of osteogenic bone formation in zebrafish after treatment to evaluate the efficacy of protecting articular cartilage; Figure 5 This is a comparison of the fluorescence intensity of osteoblasts in zebrafish after treatment to evaluate the efficacy of the treatment in improving arthritis. Figure 6 This is a typical image of bone fluorescence intensity in zebrafish after treatment to evaluate the efficacy of improving arthritis. Detailed Implementation

[0026] To make the objectives, technical solutions, and advantages of the present invention clearer, the embodiments of the present invention will be described in further detail below.

[0027] Example 1 Example 1 discloses a nutritional composition that promotes bone growth, protects articular cartilage, and improves joint inflammation, comprising the following components in parts by weight: 70 parts yak bone collagen peptides, 20 parts (shark) cartilage powder, 12 parts sweet orange powder, 0.2 parts non-denatured type II collagen, 0.002 parts vitamin K2, and 1 part sweet orange flavoring.

[0028] To verify whether the nutritional composition of the present invention has the effects of promoting bone growth, protecting articular cartilage and improving joint inflammation, the nutritional composition prepared according to Example 1 was subjected to a zebrafish test. The specific contents of the zebrafish test are as follows.

[0029] Positive control of the present invention: (a) Osteogenesis effect: Alendronate sodium tablets (hereinafter referred to as alendronate sodium), white tablets, the solvent is ultrapure water.

[0030] (II) Efficacy in improving joint inflammation: Chondroitin A sodium salt (hereinafter referred to as chondroitin sulfate), white powder, Shanghai Aladdin Biochemical Technology Co., Ltd., solvent is standard dilution water.

[0031] Animals used in this invention: (a) Promotes bone growth: Zebrafish, all of which are raised in aquaculture water at 28℃ (water quality: 200mg of quick-dissolving sea salt is added to every 1L of reverse osmosis water, conductivity is 450-550μS / cm; pH is 6.5-8.5; hardness is 50-100 mg / L CaCO3).

[0032] (ii) Effects on improving joint inflammation: In addition to meeting the conditions for promoting bone growth, it also requires Staphylococcus aureus, nutrient broth culture medium, and incubation at 37°C.

[0033] The instruments, consumables, and reagents used in the zebrafish experiments of this invention include: a dissecting microscope; a CCD camera; a motorized focusing continuous zoom fluorescence microscope; a precision electronic balance; a 6-well plate; a benchtop high-capacity low-speed centrifuge; a CO2 incubator; a clean bench; and an electronic turbidimeter. Methylcellulose (Shanghai Aladdin Biochemical Technology Co., Ltd.); dexamethasone (Shanghai Aladdin Biochemical Technology Co., Ltd.); dimethyl sulfoxide (Shanghai Aladdin Biochemical Technology Co., Ltd.); and nutrient broth culture medium (Shanghai Mingte Biotechnology Co., Ltd.).

[0034] The detection method of this invention includes: Firstly, the maximum detectable concentration (MTC) for bone function evaluation was determined: Wild-type AB strain zebrafish, 3 days post-fertilization (3 dpf), were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Samples were administered in water (concentrations shown in Table 1), and a normal control group and a model control group were also set up. Each beaker had a volume of 20 mL. Except for the normal control group, all other experimental groups were administered dexamethasone in water to establish a zebrafish osteoporosis model. After treatment at 28℃ for 4 days, the medium was changed once. After continuing treatment at 28℃ for 2 days, the MTC of the samples in the model zebrafish was measured.

[0035] Secondly, the osteogenic efficacy was evaluated: 3dpf transgenic hard-boned green fluorescent zebrafish were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples (concentrations shown in Table 2) were administered, with alendronate sodium at a concentration of 5.00 μg / mL as a positive control. A normal control group and a model control group were also set up, with each beaker containing 20 mL. Except for the normal control group, all other experimental groups were given water-soluble dexamethasone to establish a zebrafish osteoporosis model. After treatment at 28℃ for 2 days, the medium was changed once. After another 2 days of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. Data were analyzed and collected using NIS-ElementsD3.20 advanced image processing software. The osteogenic fluorescence intensity of the zebrafish was analyzed, and the statistical analysis results of this index were used to evaluate the osteogenic efficacy of the samples. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 indicated a statistically significant difference.

[0036] Thirdly, the maximum detectable concentration (MTC) was determined to evaluate the efficacy in improving joint inflammation: 3-day-fed transgenic cartilaginous green fluorescent zebrafish were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well (experimental group). The samples were administered in water (concentrations shown in Table 3), and a normal control group and a model control group were also included, with a volume of 3 mL per well. Except for the normal control group, the remaining experimental groups were treated with Staphylococcus aureus in water at 5-day-fed levels to establish a zebrafish cartilage injury model. After treatment at 28°C for 2 days, the MTC of the samples in the model zebrafish was measured.

[0037] Fourthly, (I) Protection of articular cartilage: 3-day-fed transgenic green fluorescent zebrafish were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-soluble samples (concentrations shown in Table 4) were administered, with a positive control of chondroitin sulfate at a concentration of 1000 μg / mL. A normal control group and a model control group were also set up, with a volume of 3 mL per well. Except for the normal control group, the remaining experimental groups (5-day-fed) were given Staphylococcus aureus in water to establish a zebrafish cartilage injury model. After treatment at 28℃ for 2 days, 10 zebrafish from each experimental group were randomly selected and photographed under a fluorescence microscope. Data were analyzed and collected using NIS-ElementsD3.20 advanced image processing software. The cartilage fluorescence intensity was analyzed, and the statistical analysis results of this index were used to evaluate the efficacy of the samples in improving arthritis. Statistical results are expressed as mean ± SE. The formula for calculating the efficacy of the samples in protecting articular cartilage is as follows: .

[0038] Statistical analysis using SPSS software showed that p < 0.05 was statistically significant.

[0039] (II) Evaluation of efficacy in improving joint inflammation (neutrophil count): Conditions are the same as in (I) above. Neutrophil count is analyzed, and the statistical analysis results of this indicator are used to evaluate the sample's efficacy in improving arthritis. Statistical results are expressed as mean ± SE. The formula for calculating the sample's efficacy in improving joint inflammation is as follows: .

[0040] Statistical analysis using SPSS software showed that p < 0.05 was statistically significant.

[0041] The above is the content of the zebrafish experiment of this invention. The following is the result analysis of each part of the zebrafish experiment.

[0042] Maximum detectable concentration (MTC) results for bone-promoting efficacy: Under the experimental conditions, the bone-promoting MTC of the nutritional composition prepared in Example 1 (Jiaxiang Companion as shown in the figure, the same below) was 7.81 μg / mL, as shown in Table 1. Subsequent experiments were conducted using this maximum detectable concentration.

[0043] Table 1 Results of the concentration exploratory test for bone-promoting efficacy of samples (n=30)

[0044] Evaluation results of bone-promoting efficacy: Under the experimental conditions, the nutritional composition prepared in Example 1 exhibited bone-promoting efficacy, specifically demonstrating an effect of increasing bone density. The results are shown in Table 2 and... Figure 1-2 As shown.

[0045] Table 2 Results of the bone-promoting efficacy evaluation test of the samples (n=10)

[0046] Note: Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001.

[0047] Maximum detectable concentration (MTC) results for improving osteoarthritis: Under the conditions of this experiment, the MTC of the nutritional composition prepared in Example 1 for improving arthritis was 31.2 μg / mL, as shown in Table 3.

[0048] Table 3 Results of the concentration exploratory test for improving joint inflammation (n=30)

[0049] Evaluation of the efficacy in protecting articular cartilage and improving arthritis: Under the experimental conditions, the nutritional composition prepared in Example 1 demonstrated the efficacy in protecting articular cartilage and improving joint inflammation. The results are shown in Tables 4-5 and... Figure 3-6 As shown.

[0050] Table 4. Results of the test evaluating the efficacy of articular cartilage protection (n=10)

[0051] Note: Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001.

[0052] Table 5. Results of the efficacy evaluation test for improving joint inflammation of the samples (n=10)

[0053] Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001.

[0054] The zebrafish test results above show that the nutritional composition provided by the present invention has a good osteogenic effect when the concentration is 7.81 μg / mL, with an osteogenic fluorescence intensity of 2545346; and when the concentration is 31.2 μg / mL, it can reduce the number of neutrophils, effectively improve joint inflammation, and relieve pain.

[0055] Example 2 Example 2 discloses a nutritional composition that promotes bone growth, protects articular cartilage, and improves joint inflammation, comprising the following components in parts by weight: 65 parts yak bone collagen peptides, 18 parts (shark) cartilage powder, 10 parts sweet orange powder, 0.3 parts non-denatured type II collagen, 0.003 parts vitamin K2, and 1 part sweet orange flavoring.

[0056] Example 3 Example 3 discloses a nutritional composition that promotes bone growth, protects articular cartilage, and improves joint inflammation, comprising the following components in parts by weight: 70 parts yak bone collagen peptides, 16 parts (shark) cartilage powder, 15 parts strawberry powder, 0.2 parts non-denatured type II collagen, 0.003 parts vitamin K2, and 1 part strawberry flavoring.

[0057] Example 4 Example 4 discloses a nutritional composition that promotes bone growth, protects articular cartilage, and improves joint inflammation, comprising the following components in parts by weight: 75 parts yak bone collagen peptides, 18 parts (shark) cartilage powder, 14 parts sweet orange powder, 0.25 parts non-denatured type II collagen, and 0.002 parts vitamin K2.

[0058] Example 5 Example 5 discloses a nutritional composition that promotes bone growth, protects articular cartilage, and improves joint inflammation, comprising the following components in parts by weight: 72 parts yak bone collagen peptides, 16 parts (shark) cartilage powder, 11 parts blueberry powder, 0.2 parts non-denatured type II collagen, 0.003 parts vitamin K2, and 1 part blueberry flavoring.

[0059] Comparative Example 1 It is basically the same as Example 1, except that there is no non-denatured type II collagen.

[0060] Comparative Example 2 It is basically the same as Example 2, except that it does not contain vitamin K2.

[0061] Comparative Example 3 It is basically the same as Example 1, except that it does not contain non-denatured type II collagen and vitamin K2.

[0062] Comparative Example 4 It is basically the same as Example 1, except that (chicken) cartilage powder is used instead of (shark) cartilage powder.

[0063] Comparative Example 5 It is basically the same as Example 1, except that salmon nasal cartilage powder is used instead of (shark) cartilage powder.

[0064] Comparative Example 6 It is basically the same as Example 1, except that bovine bone collagen peptides are used instead of yak bone collagen peptides.

[0065] Comparative Example 7 It is basically the same as Example 1, except that fish collagen peptides are used instead of yak bone collagen peptides.

[0066] Comparative Example 8 It is basically the same as Example 1, except that bovine bone collagen peptides and yak bone collagen peptides are used, and the mass ratio of bovine bone collagen peptides to yak bone collagen peptides is 1:1.

[0067] The effects of the above embodiments and comparative examples were tested, as follows: I. Regarding the relief of joint pain 104 participants were selected for the trial, excluding individuals with fractures, osteonecrosis, paralysis, or those taking other medications to improve bone density. Individuals experiencing severe joint pain while walking, requiring crutches or support, were chosen to observe whether the medication improved their pain and allowed them to walk slowly without assistance. A total of 52 men and 52 women were selected, including 26 men and 26 women aged 60-70 (52 total) and 26 men and 26 women aged 71-75 (52 total). Each group consisted of 8 participants: 2 men and 2 women aged 60-70, and 2 men and 2 women aged 71-75, for a total of 13 groups. The trial lasted 21 days, with a dosage of 2.5g twice daily. Improvement and ineffectiveness in joint pain were recorded, and the effectiveness rate was calculated as: Effectiveness rate = (Number of participants with improved joint pain / Total number of participants) * 100%. The results are shown in Table 6. Table 6 Effect of relieving joint pain

[0068] II. Bone density detection Bone density refers to the content of minerals (mainly calcium and phosphorus) in bone per unit volume. It is a key indicator to measure bone strength. The T value (T-Score) is the most important diagnostic indicator, which is a value obtained by comparing the bone density of an individual with the peak bone density of healthy young adults. When -2.5 < T value < -1.0, it indicates osteopenia. The trial subjects excluded those with fractures, osteonecrosis, paralysis, etc. and those taking other drugs to improve bone density. A total of 104 people were selected for detection, including 26 men and 26 women aged 60 - 70 years old, a total of 52 people; 26 men and 26 women aged 71 - 75 years old, a total of 52 people. They were divided into 13 groups, with 8 people in each group. Before starting the trial, bone density was measured in the same hospital and the initial data were recorded. Then, each nutritional composition was taken for 21 days at a dose of 2.5 g / time, 2 times / day. After 21 days, bone density was measured. The data of the detection were analyzed using SPPS 27 software, and the average value of each group was taken as the result, as shown in Table 7.

[0069] Table 7 Changes in bone density before and after the trial

[0070] As can be seen from Tables 6 and 7, the effective rate of the nutritional composition of this patent in relieving joint pain reaches over 85%. Before the trial, the bone density was -2.30 - -2.50 / cm 3 , and after the trial, the bone density was -2.05 - -2.20 g / cm 3 , with significant effects.

[0071] As can be seen from Comparative Examples 1 - 3, although the dosages of non - denatured type II collagen and vitamin K2 are small, in the nutritional composition of this patent, they can significantly enhance the effects of yak bone collagen peptide and (shark) cartilage powder. As can be seen from Comparative Examples 4 - 5, in the nutritional composition of this patent, if other cartilage powders are used to replace (shark) cartilage powder, the effects are not good. As can be seen from Comparative Examples 6 - 8, if other collagens are used to replace yak bone collagen peptide or other collagens are mixed with yak bone collagen peptide, the effects are not good. That is, the yak bone collagen peptide, (shark) cartilage powder, fruit powder, non - denatured type II collagen and vitamin K2 in this patent act synergistically to achieve very good effects.

[0072] Although the above - mentioned examples and comparative examples have described the present invention in detail, they are only a part of the examples and comparative examples of the present invention, rather than all of them. Other examples can be obtained according to this example without creative work, and these examples all fall within the protection scope of the present invention.

Claims

1. A nutritional composition for promoting bone, protecting articular cartilage and ameliorating inflammation of the joint, characterized in that, The composition comprises the following components in parts by weight: 60-80 parts of yak bone collagen peptide, 15-25 parts of (shark) cartilage powder, 8-16 parts of fruit powder, 0.1-0.3 parts of non-denatured type II collagen, and 0.002-0.004 parts of vitamin K2.

2. The nutritional composition according to claim 1, characterized in that, The composition further comprises a flavoring agent in an amount of 0.5-1.5 parts.

3. The nutritional composition according to claim 2, characterized in that, The fruit powder is selected from strawberry powder, sweet orange powder, or blueberry powder, and the flavoring agent is selected from strawberry flavoring agent, sweet orange flavoring agent, or blueberry flavoring agent.

4. The nutritional composition of claim 2, wherein, The fruit powder is selected from sweet orange powder, and the flavoring agent is selected from sweet orange flavoring agent.

5. The nutritional composition of claim 1, wherein, The composition comprises the following components in parts by weight: 70 parts of yak bone collagen peptide, 20 parts of (shark) cartilage powder, 12 parts of fruit powder, 0.2 parts of non-denatured type II collagen, and 0.002 parts of vitamin K2.

6. The nutritional composition of claim 2, wherein, The composition comprises the following components in parts by weight: 70 parts of yak bone collagen peptide, 20 parts of (shark) cartilage powder, 12 parts of sweet orange powder, 0.2 parts of non-denatured type II collagen, 0.002 parts of vitamin K2, and 1 part of sweet orange flavoring agent.

7. Process for the preparation of a nutritional composition according to any one of claims 1 to 6, characterized in that, The method comprises: S1: uniformly mixing (shark) cartilage powder, non-denatured type II collagen, vitamin K2, and a flavoring agent in a predetermined ratio to obtain a premix; S2: uniformly mixing the premix in step S1, yak bone collagen peptide, and fruit powder to obtain an intermediate product; S3: packaging the intermediate product in step S2 to obtain a product.

Images